Eli Lilly and Company selected Huntsville, Alabama, for a new $6 billion manufacturing plant. Lilly will dedicate the facility to producing Active Pharmaceutical Ingredients (APIs) for its portfolio of peptide and small-molecule drugs. This critically includes the oral GLP-1 weight-loss medication, orforglipron.
The move is part of Lilly’s broader strategy to bolster domestic manufacturing capabilities. The company seeks to address surging global demand for its incretin-based medicines, which treat diabetes and obesity.
The investment is expected to create approximately 450 permanent jobs for engineers, scientists, and operations personnel. The project will also generate an estimated 3,000 construction jobs.
Construction on the new site is slated to begin in 2026. The facility is projected to be completed and operational by 2032. This plant is one of several new large-scale U.S. manufacturing sites Lilly is building to strengthen its supply chain for key products.